Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree completely Mav
18 million locked up here for dimes... thats plural!!!
Although, in other OTC stocks, i would typically sell a fraction of my shares for pennies, in this case, the existing revenue stream, blockchain implementation plans, best in class/ award platform, on going discussions with other industries (e.g., agriculture, courier fleet, RV camping), share restructure, proven CEO in building shareholder value, and many more, the potential is just too great!!!
... and given the high failure rate of many otc stocks, I refuse to allow impatience to lure me down the path of selling for the next potential big thing!!!
However, I have done very well by hedging my investments with broad diversification... this allows me to keep the unicorns like this one for the longer term... and bigger payout... and btw, longer term here is only a few months away... win / win scenario in the making!!
Yup...
and the company said that their blockchain business strategy would be revealed in Q2 2018... any day now
BTW... It is not atypical for "products under the pharmaceutical FSS to be unavailable via a website but either direct order from the manufacturer / contractor or government pharmaceutical prime vendor"
Refer to email below
Chris,
I am redirecting your inquiry to Diana Lawal, Chief – Pharm/Dental Team. Ms. Lawal manages the Federal Supply Schedule (FSS) program for pharmaceuticals. Ms. Lawal telephone number is 708-786-4949 or email diana.lawal@va.gov. Please be advise products under the pharmaceutical FSS are not available via a website but either direct order from the manufacturer/contractor or government pharmaceutical prime vendor.
Kind Regards,
W. R. (Bob) Satterfield, III
W. R. (Bob) Satterfield, III | U.S. Department of Veterans Affairs
Chief - Contracting Branch | VA Federal Supply Schedule Service
P.O. Box 76, 1st Avenue, One Block North of 22nd Street, Hines, IL 60141
office: 708.786.4955 | cell: 708-305-9974 | fax: 708.786.5170 | william.satterfield@va.gov
Excellence: by Everyone, Every Day, Every Time
Please take a moment to complete our Customer Service Survey http://www.va.gov/nac/customersurvey/
Visit VA FSS Online: www.fss.va.gov | http://www.linkedin.com/pub/va-fss-service/34/166/711
http://interact.gsa.gov/users/va-fss-service | http://www.fss.va.gov/fss/pressreleases/pressrel_rss.xml
Confidentiality Note: This e-mail is intended only for the person to whom it is addressed and may contain information that is privileged, confidential, or otherwise protected from disclosure. Dissemination, distribution, or copying of this e-mail or the information herein by anyone other than the intended recipient is prohibited. If you have received this e-mail in error, please notify by reply e-mail and destroy the original message and all copies.
So, is $1 million of net sales in Q1 2010 a lie too?... check the 10Q for yourself.
This year's 10-Q will mark the beginning of a great year... You either jump on board before or after the curtain is drawn.. best of luck either way ( :
FYI...
I'm still long and strong here folks!!!
I've curtailed my postings here due to the numerous posting of false and misleading information.
Nonetheless, i have been in constant contact with the EuroAmerican IP CEO and the Branch Chief – Contracting Branch - Pharmacy & Dental Division at the VA Federal Supply Schedule.
Based on my discussions, it has been confirmed that Nyloxin CAN and IS currently being ordered by the VA and military procurement departments.
As I've continued to say (and you can refer to my previous posts as evidence), the hospitals were instructed to order the product through the "open market". Apparently, I'm the only one contacting the Branch Chief for Pharmacy and Dental Div at the VA FSS, as she specifically told me so... haha
And as indicated previously by the CEO of EuroAmerican IP, the product is selling very well.
Folks, we don't need the FSS listing, as the government procurement departments are aware of the product and are ordering it on the open market... As I've said before, Debra is offering the same bulk discounts through her website.
Connecting the dots here, this means that we could see significant revenue for this quarter!!!.. and the 10-Q should confirm next month IMO
I just received a response to my Tecnu email last week. Let me know if you have any follow up questions but i would think that the distributor would have inquired or informed the manufacturer if clinical trials were required for the uplisting... based on this, i am still convinced that the FSS listing on gsa website will occur once the SIN# is assigned...This corroborates with the EuroAmerican CEO's statement to me as well... patience will prevail here
Gary Burris <Gary@teclabsinc.com>
To:XXX@yahoo.com
?Apr? ?23 at ?10?:?03? ?AM
Hello, Chris
I just received your email. Thank you very much for sending it and for considering our products.
You asked if GSA required any clinical trials for the listing of our poison ivy spray (Tecnu Rash Relief Spray). As the manufacturer, we did not list the product on GSA Advantage. However, some of our distributors (resellers) may have listed the item. Although we didn’t personally list the item, it is my understanding that clinical trials are not required for listing an over-the-counter pharmaceutical product like our Rash Relief Spay. Also, we don’t have a separate clinical trial for Tecnu Rash Relief Spray since clinical trials are not required by the FDA for this type of product.
If you let me know your situation, or what your group of veterans is looking for in regards to a poison ivy product (what do you want the product to do?) I can give you some direction as to which product(s) would help you solve your poison ivy problem most effectively. For example, is your group looking for a product to help stop spreading of the rash, or help a person avoid the rash in the first place? Or are you looking for a product to just help with the itching and oozing of an existing rash?
I do training for forestry workers, wildland fire fighters, etc. in regard to poison oak and ivy safety. So I’d love to give you information to help you solve your problem in the most efficient and cost effective way.
Thank you, Chris.
Sincerely,
Gary Burris
Tec Labs
541-918-4124 direct
From: info@teclabsinc.com <info@teclabsinc.com>
Sent: Saturday, April 21, 2018 7:35 AM
To: Lisa Muller <lisa.muller@teclabs.com>; Janelle Nichols <jnichols@teclabs.com>
Subject: A new question has been submitted on teclabsinc.com
A new question has been submitted via the Ask a Question form on the Tec Labs web site (http://www.teclabsinc.com/tips-advice/qa/ask-a-question).
To whom it may concern,
I saw your poison ivy spray on the gsaAdvantage site, and I was going to recommend the purchase to my grouo of veterans.
Could you please clarify if gsa required any clinical trials for the listing... not that it matters to my group of survivalist but my director may ask prior to purchase.
Thank you kindly for your consideration.
Regards,
Chris
How many letters in Tecnu?:
5
I'm renting a U Haul this weekend and just realized how revolutionary this IP could be in optimizing consumers' mileage efficiencies.
In Cali, u-haul will charge .71 for every mile accrued beyond the truck package deal.... i'm spending about $150 to move my son about a half hour away.
Im sure, if youre like me u try to return the truck with the cheapest and minimum required gas... I've actually helped people move that will drive miles to get the cheapest gas... and they sometimes have to fuel up twice aa they typically under shoot the minimum fill up on the return... they actually end up paying at least $10 more than the price they would pay if the fuel up process was managed better.
U- haul could use the data to determine if they should top off the gas tanks prior to each customer's use... this will create cost savings to the customer and thus more business for U haul.... athis is one example of how this company could shift the paradigm in fleet management.
U haul could also evaluate the driving patterns of consumers'
and strategically close or open shops in areas that will generate the most business.
There are many more examples... and they apply to taxis, postal, RV, military, etc... huge upside coming soon!!
Nice try...
But Xenacare was our distributor when the product was in Walgreens, CVS, and many other brick and mortar retail stores between 2009 and 2011... and the market cap was 220 million with approximately 1 million in net sales per quarter... read the quarterlies will ya!
«Note: the market cap was adjusted in order to reflect the 1:40 split in 2015»
Thanks Mav...
Yesterday I sent an email to Tecnu poison ivy manufacturer inquiring on their pathway to gsa approval.
Although they are closed on the weekend, i will share any info here if I hear back.
Hi Gem....
I'm not sure who is funding the trials at the VA but i was told by Debra that the trials ARE 'in progres"... I remember this very soecifically, as well as the fact that sales directly to the veterans are 'very good"... this corroborates with my personal notes on our discussion as well as RIM's email from Rik.
She didn't know specifically how long the trials would take.
Regarding your question about whether the trials are necessary to list on the FSS, I honestly don't know.
However, I can surmise that they are not required, given the fact that Rik has always indicated that he wants to complete a comparison study... This has been stated in previous 10-qs and outside the context of the gsa listing.
I personally believe the trials are a separate pathway that he is pursuing... I further believe that they are not required based on Debra's statement that the gsa review team is ALREADY evaluating a new SIN# for our product!... Based on this, I believe the gsa listing could happen any day now... Folks are getting caught up with the fact that the listing was removed in a week when all my DD suggests that it was an administrative error that will be resolved very soon.
The gsa FSS also currently lists other homeopathic medication so any claim that gsa does not have homeopathic medication is false... and it's highly doubtful that clinical trials were required for their uplisting... in fact the contrary is true for homeopathic medication.... hope this helps ( :
Please explain why the company had net sales of $864,424 in Q1 2010 then!!!... and today, we have potential military contracts in gsa, Department of Defense (nerve agent) trials, JV partnership discussions, and many more clinical trials than before... companies with much less pipeline products and NO revenue are trading at much higher than our current market cap!!
How would your opinion change if any one (1) of the military contract(s), retail contract(s), JV partnership, and / or clinical trial catalysts come to fruition?
Its happened before..."historically speaking", the product was previously shelfed in Walgreens , CVS, and many other brick and mortar retail stores... and sales were incredible!!!... the market cap was 220 million, which is about a dime at current S/S!!
So, if you want to speak of this company's history, please be unbiased enough to be comprehensive in your evaluation... not omitting factual info that doesn't support your own trading agenda
This corroborates perfectly with what the EuroAmerican CEO told me when she said that she was offering the same bulk rate discount directly to the veterans on the open market until gsa approves... please refer to my previous posts a couple weeks ago.
Also, just to clarify, the gsa didn't withdraw the product due to its homeopathic claim but moreso because there isn't a SIN# classification for this specific type of homeopathic product...they currently have a very limited listing of homeopathic products... check the site for homeopathic skin tag remover and poison ivy spray as evidence.
As such, the clinical product review committee is evaluating the assignment of a new SIN# concurrent with the VA's 2 clinical trials that intend to compare the efficacy to the opioids... all explained previously in my posts
For those who persistently try to undermine our EuroAmerican IP and NXGen distributors based on "years in business" or size alone....
Check out our previous distributor for Nyloxin (then called Cobroxin) product in 2009 / 2010:
At the time, the product was in CVS, Walgreens, and many other retail brick and mortor stores... However, due to a breach of contract by the distributor, Nutrapharma severed the relationship in 2011... and yes, at the time, the distributor was new to business with few employees.... but nonetheless, Nutrapharma stock was trading at $1 with a market cap of 220 million <adjusted for the 1/40 stock split on 05/18/15>... execution trumps time on the job any day... refer to Bill Gates, Steve Jobs, and Mark Zukkenburg as examples.
However, once the gsa approves and more retail contracts are established this market cap will seem marginal VERY SOON!!!... add in the mix any announcement of a JV partnership and the pursuit of more clinical trials and our stock price could be multi dimes / quarters EVEN SOONER!
...and here we sit at approximately a market cap of 50Xs less than previous years with hundreds of times more potential.
Xenacare distributor
Cobroxin in Walgreens
Cobroxin in CVS
Hi Colworth....
Did you hear any details regarding the payment platform for the RV sales?
Just speculating here, but the company has previously indicated that their blockchain implementation strategy would be revealed in Quarter 2... and now we hear that there may be this RV contract in Quarater 2!
Aside from the obvious blockchain application, this strategy not only aligns with the company's stated intent to enter other industries but would also reflect the forward thinking business mentality of Marcus Lemonis the CEO.
My bad...
Rough day here... and I got a little carried away... Please disregard the clinical trial verbiage <intended for another stock>.... thanks Mav for the PM ( :
I'm sorry Fly...
With the CTO revoked, it's doubtful that you'll have the opportunity to buy cheaper tomorrow... However, CONGRATULATIONS on today's buy!!!... it demonstrates your strong courage and conviction in this company... I would've bought more today as well but i just didnt have the funds ) :
The stop sign will likely come off tomorrow as well, and all we'll be left with is a big FAT PR related to some RV Fleet contract, agrigultural contract, gsa update (or potential military contract) blockchain implementation strategy (any day now: company said quarter 2 update), potential stock buy back, Phase II MS trial, potential fast track clinical trial for nerve agent IP, yada yada ya
Congratulations to everybody else who either started a position or increased their holdings... You will be richly rewarded in the very near future...like tomorrow (haha)... and many weeks, months, and years to follow
Colworth...
I have some good ideas re: this strategy, but in your opinion, what challenges would RV tracking solve in the camping world?
In the golf world, Pace of play and fleet management is improved
I'm not sure Fly...
i can only surmise that there was an error in the SIN categorization that was discovered a week later. I was actually surprised it was listed so quickly anyways.
I was told that the CPRC is evaluating a unique SIN # for this product.
Correction...
I found the reference to EuroAmerican IP in the 10K... It says:
"They are working on registrations with government contracts through the US-General Administration (GSA Advantage) website at www. gsaadvantage.gov"
Dudes and Lindy....
Why all the long faces?!!!!... and doubt now???
I thought this group understood the fact that this 10K reflects business operations through Dec of last year.. REPEAT... last year!!!... All the seasoned investors have been saying this for weeks now... Even the cover page of the 10K specifically says that the report is for the fiscal year ending Dec 31, 2017.
This means that all content related to delays, insufficient funding, yada, yada, are applicable to last year's performance... The reason this 10k has no substance is because the funding, distributorships, human clincal trials, GSA clinical product review, and other catalysts occurred in quarter 1 2018... really not sure why so many here are shocked that the 10K appears to be a cut and paste of previous guidance.. it actually is!!!... there was little progress last year due to the toxic funding.
As many here have alluded to, the current performance of the company will be revealed in upcoming PRs... they typically come after the 10K release... and as we know, there are many activities happening behind the scenes now that funding is more favorable... and since my initial discussion with EuroAmerica's CEO, I've had other discussions re-confirming that human clinical trials are IN PROGRESS!!!... you can call her yourself if you're so inclined to confirm... her number and email are listed on the EuroAmerica's website.
Nutra Pharma won't confirm the trials in this 10K as this 10K is pertinent to last year's performance. Could someone please confirm, but i don't even recall seeing EuroAmerica's distributorship listed in this 10K, despite mention of the Australia distributorship and the nerve agent PR in Feb 2018... IMO, this is because the details could be a potential PR soon
Having said that, i personally suspect that we will get a PR very soon and definitely before the Q1 10-Q release in mid May... wouldn't be shocked to see one tomorrow or later this week.
So, don't let the doom and gloomers steal your shares...they know the potential of this company. Otherwise they simply wouldn't be wasting their time trying to convince you to sell... think about it!!
Yes....
Any announcement on the 2 trials currently being executed at the VA medical centers will validate the following:
1. The company has sufficient funding.
2. The company is finally gaining traction towards its stated goal of replacing the current opioids with Nyloxin in the military... this is a minimum $6.5 million market, based on 2012 data, and the company has streadfastly proclained its intent in the last 4 years of 10Qs.
3. The opioid crisis has met a threshhold level for the government and the government is now taking action... this was confirmed by the euroamerican CEO where she stated that the GSA' clinical product review committee is evaluating a unique SIN # as the product doesnt fit into any existing homeopathic category.
4. And on a separate pathway, and given the company's more funded state, it is more likely to begin phase II MS studies.
All of the above have challenged the company for years despite a significantly higher market cap in previous years!!!
So... fastforwarding to now!!!
Here we sit at an all time low MC evaluation and an all time high potential for a huge military contract and pH II clinical trial initiation with orphan drug status!!!... my friends, specifically the newer investors here, this is exactly what a multi bagger looks like in the making... and the timing is now!!!
And with their nerve agent patent, the state of international unrest, their connections in the DOJ, like strategic advisor ret. Gen Maj Kenneth Dowd, this stock is a hedge against the broader market and a defense play!!!
And Mav....
Even at the 140 million MC, the company wasn't even close to gsa approval.. they lacked the funding to complete the two (2) human trials aimed at proving Nyloxin's superior efficacy over opioid prescription pain relievers.
The company has stated in previous Q1 2014 10-Q:
"We are working with outside consultants to register Nyloxin ® Military Strength and the other Nyloxin ® products for sale to the US government and the various arms of the military as well as the Veteran's Administration. On April 22, 2014, we announced that we are seeking GSA (Government Services Administration) Certification in order to supply Military Strength Nyloxin ® to the Department of Defense (DoD) and Veterans Affairs Hospitals (VA).
...Additionally, we plan to complete two human clinical studies aimed at comparing the ability of Nyloxin Extra Strength to REPLACE prescription pain relievers."
And now, we have the appointment of Maj. Gen. Kenneth Dowd, US Army (Ret.) as Strategic Advisor for NutraPharma's newly created 'Military & Veterans' business segment. Major General Dowd was Director of Logistics Operations for the Defense Logistics Agency (DLA) amongst other high ranking roles during his 30 year service... Refer to Aug 2016 PR by company
We have a distributor partnership with EuroAmerican IP.
We have funding for the 2 human trials.
We have 2 human trials that are ONGOING as confirmed by the EuroAmerican CEO.
We have a gsa Advantage CPRC steering committee working on the assignment of a new SIN#... my personal opinion is that the gsa FSS does not have an SIN classification for a homeopathic animal extactable (venom)... most homeopathic products are botanical or animal part based (e.g, shark cartilage)
And, as such, we have the very real possibility to seize the majority of the approximate 10 million opioid prescription prescribed to military personnel per year!!
And here we sit at approximately 4 million MC with so much more going on than the 140 million MC of many years ago.
This will be nickels, dimes, and quarters very soon...then dollars soon thereafter... HUGE PARADIGM SHIFT IN PAIN MANAGEMENT!!...with government support... community support...big pharma on the ropes with multiple lawsuits... big pharma looking for an effective alternative (with cash on hand).
...all to be revealed in days, weeks, and months...NOT YEARS FOLKS!!!!!...could actually start this week in my opinion!
Point taken....
But why did you omit this week's facts regarding EuroAmerican CEO's disclosure that selected VA medical centers were undergoing TWO (2) trials... she specifically said 2!!... and she specifically characterized them as "in progress"
...and is it coincidental that the number of trials she mentioned is exactly the number of trials that Nutrapharma has been planning to execute, but delayed due to insufficient financing... read the Q1 2014 10-k
Is it also coincidental that the company just procured recent financing.
Is it also coincidental that the Q1 2014 10-k states that the intent of the extra strength Nyloxin is to replace the current prescription pain relievers... and the extra strength Nyloxin is the military version.. and the military version is targetted for the gsa website...if you agree with the facts, as stated by the company, then you can only conclude that the extra strength Nyloxin will REPLACE THE 6.5 MILLION OPIOID PRESCRIPTIONS TO MILITARY MEMBERS PER YEAR. The only facts that remain are the addition of the product to the GSA FSS and the forthcoming sales, which will be MASSIVE!!... However if you are waiting for these final facts to be confirmed, ignoring the "writing on the wall" DD, then you my friend are a reactionary investor and will pay many multiples (logarthms) higher... respectfully, this is a fact!
Additional facts reveal that government research shows that 1-in-7 active duty Army service members are on prescription opioids, and that 25% of them meet the clinical criteria for substance dependence (Army, 2012). Prescriptions for pain relief written by military physicians quadrupled between 2001 and 2009. For veterans, in the eleven years from 2001 to 2012, VA prescriptions for the opioid hydrocodone increased by 4,100% percent. The importance of opioid misuse and abuse continues to be covered extensively in both the public and the military media.
And what about the reported fact that some 7,600 Americans die from use of non-steroidal-anti-inflammatory drugs (NSAIDs) and another 78,000 are hospitalized. Using NSAIDs such as Ibuprofen in high doses for chronic pain leads to potential for critical health risks, including stomach problems, internal bleeding and even kidney failure. There are significantly greater health risks with NSAIDs when abuse of this drug is combined with alcohol intake.
In total there are roughly 70,000 Americans that die from opioids a year.
May you choose your facts wisely ( :...best of luck to all here
As confirmed in the the Q1 2014 10-k (snipet below) and the CEO of EuroAmerican IP earlier this week, NutraPharm now has the funds to begin the 2 clinical trials they've been planning... it's no coincidence that the EuroAmerican IP CEO specifically mentioned the ongoing 2 trials at selected VA medical centers... AND THE INTENT IS TO "REPLACE PRESCRIPTION PAIN RELIEVERS ON THE GSA SITE!!!! ... remember the extra strength Nyloxin is the military grade for bullet wounds.... check the 10-K yourself on the OTC page....I'm telling you, the VA is taking this contract very seriously and will assign a new SIN # soon!!!... THIS IS HUGE!!!!
"We are pursuing international drug registrations in Canada, Mexico, India, Central and South America and Europe. Since European rules for
homeopathic drugs are different than the rules in the US, we cannot estimate when this process will be completed. Additionally, we plan to
complete two human clinical studies aimed at comparing the ability of Nyloxin Extra Strength to replace prescription pain relievers. We
originally believed that these studies would begin during the second quarter of 2010; however, these studies have been delayed because of lack
of funding. We cannot provide any timeline for these studies until adequate financing is available"
Today's restructure PR by the attorney officially marks the end of the quiet period.... and the cheapies.
This is why Fly, I, and many others have have been ecstatic about buying at the day's high for the last couple of days...methodic accumulation!!
Those that heeded will be richly rewarded tomorrow and next week!!... give or take a day or two... haha
Very exciting times ahead folks!!!
Yup...
And works significantly better than all the opioid alternatives... without addiction and side effects.
I can only lead a horse to water, but consider this...
There is a very specific reason why the CEO of EuroAmerican IP told me that the military strength Nyloxin is used for bullet holes... as she said, there are 2 separare trials that are currently underway by the VA... the Clinical Product Review Committee is actually evaluating the need for a unique SIN # classification for this product... think about that for a moment and then determine for yourself how serious the government is in adding it to the gsa FSS registry.
... and consider the above in the context of Nutra's nerve agent patent, pre clinical testing with the gov, and the current sign of times... eg Syria.
This is a huge military contract in the making ... and global paradigm shift for pain management... add into the equation, the MS phase II trial to be announced any day.
I could go on and on, but gotta go... read Fly,s DD for all the other catalysts and epic unmet need here
Yes sir fly...
It's called dollar cost averaging... since no one can time the market, you buy periodically thru a company's PRE-growth phase... you really can't lose with a market cap as low as we have here...and with such potential..and despite the fact that I bought at yesterday's high, my dollar cost average is still .003!!!... testament to the above!!
Folks will be saying the same at a dollar cost average of pennies... then nickels... and dimes... choose your average!!!
Mutual funds do it all the time... simple formula to wealth... for those who have the courage and conviction to win!!!... repeat and rinse
Like you Fly...
I added 4 milly at the high yesterday... wasn't concerned in the least that it dipped to the 5s moments after... haha... all good here.
This move to .008 and beyond will be MUCH MUCH stronger than the move a couple weeks ago... the company said that they will reveal their blockchain strategy in Q2... so any day now!!!
And with Chesapeake Group's involvement, we know that there will be some merger / acquisition deal.
Put that together with the best in class software, stellar management team with proven success, recurring subscription sales, recent $3 million PO, and advertising revenue of $75,000 per golf courses...that's $19 million in high margin advertising alone!!!... the path to $11 has begun... for new investors here, if that doesnt make sense, please read the DD more ( :
HUGE HUGE UPSIDE POTENTIAL!!!
Like I said Monday, i was happy to slap the 6's for another 4 million... didnt even care that it dipped to 5s
Wow...
I forgot to even factor that in... lol
And this is not just an opioid replacement play, but it's also a defense play during international conflict... and here we sit right dab in the middle of both at 4 million MC.... and multi gov clinical Product review...HUUUUUUGE
I'm just sitting back enjoying the price action... ive been buying since the trips to .0045!!!!!
The price is a steal right now!!!
Hi Gem....
Im not sure if Debra knew the scope or duration and i didnt ask her specifically as I was acting as a consumer... not investor...my primary intent was to get more validation from the sales front... to which she said that it was selling very well through the open market... EVEN WITHOUT GSA... shes offering the same bulk discount as GSA to veterans... in hindsight I wish I had prepared better questions but I didn't know I would be talking directly to her
The last time, I talked to a gsa rep who had no knowledge of the process... but I'm beginning to think that other military contracts is Rik's goal... think about it... why would Rik PR the plan to distribute in other countries when the citizens could just purchase directly from Amazon now.
The potential for international gov contracts is beyond huge... all at a time when opioids are killing 70,000 a year in America alone... and lawsuits by the government.
My conservative price target in the next few months is .05 as people figure out Rik's retail and military rollout plan... as confirmed by increased sales in the next quarters... much more than the $4 million evaluation today for sure!!!!
Exactly Mav...
and don't forget the initiation of Phase II clinical on MS.
BTW, the 2 GSA trials are common practice prior to FSS listing of a homeopathic product... the Australia and New Zealand governments are presumably doing the same thing... all par for the course...as Rik stated a couple months ago, the products would be available in Aus and New Zeal later this year.
He's also pursuing other governments like India, Spain, etc... all to be announced shortly... once the CPRC approves in America, the other governments will follow suit in short order... I know Rik has already talked to the other governments and is waiting for GSA approval....HUGE INTERNATIONAL MILITARY CONTRACTS IS THE GOAL HERE!!!
As the technical traders know, the base at these churning levels is very strong... those who wait for lower prices will miss the bigger payout at increments of .01... instead the fence sitters and fippers squabble over .0001... haha.
I wouldn't be surprised to see revenue from veterans in Q1 as Debra said that she is extending the bulk discounts to them on the open market until the CPRC approves... she said her team is marketing directly to the veterans at the VA medical centers across the US... if anyone has any VA site head, head nurses, or other VA dr contacts, let me know and I will fwd to her.... especially any personal drs at the VA medical center in Brentwood, los angeles , CA... in order to get background info more casually I told her that a relative is a veteran at that loxation... small white lie...she asked for info so she can fly out for marketing
BTW, I spoke directly to Debra, the CEO of EuroAmerican last nite... very passionate lady who uses the product herself... she said the regular strength product is incredible and is selling extremely well on the website... The military strength product is intended for battle injuries like bullet wounds... BULLET WOUNDS FOLKS!!!!... That's how crazy effective this product is!!!
Correct me if I'm wrong Fly, but i recall reading a PR somewhere that the product is 600 times more effective than morphine.
The two (2) GSA trials are necessary in order to be listed on FSS due to the homeopathic claim; the product is currently under review by CPRC (Clinical Product Review Committee) as there is currently no SIN# that correctly categorizes the product; the CPRC is reviewing whether a new SIN# is needed.
IT'S COMING!!!...
I added .017s last week and haven't sold one share since original purchase in trips
I NOW have very good reason to believe that the recent non dilutive funding is intended for the initiation of Phase II MS trials and ongoing trial testing... yes "ongoing"... at selected Veteran Affair Medical Centers.
IN MY OPINION ( ;, Rik and our EuroAmerican IP distributor have been working diligently with GSA Advantage's CPRC steering committee... big news to follow shortly!!!... all of the above is stated as my opinion.